[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"enoxaparin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:enoxaparin":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100543556",false,"NCT06357403","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients: a Prospective Multicentre Cohort Study","AntiXa-ICU","Inclusion Criteria:\n\n* Age over 18 years at the time of intensive care unit admission\n* Admission to a participating intensive care unit within the last 24 hours\n* Expected discharge is later than 48 hours after enrolment\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE\u002Fkg when given twice daily or of at least 150 IE\u002Fkg when given once daily\n* Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment\n* Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period\n* Estimated life expectancy below 48 hours or comfort terminal care order in place\n* Previously diagnosed heparin-induced thrombocytopenia\n* Pre-operative admission for elective surgery\n* Previous enrolment in the study","ALL","18 Years",{"count":19,"type":20},1300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and\u002For pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are:\n\n* What is the association between antiXa and VTE?\n* What is the association between antiXa and symptomatic, respectively incidental, VTE?\n* How is pharmacological anticoagulation with enoxaparin related to measured antiXa?\n* What is the association between antiXa and bleeding complications.\n* What is the incidence of venous thromboembolism in patients treated at an intensive care unit?\n* How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit\u002Fhospital.",[24,25,26],"Thrombosis","Pulmonary Embolism","Enoxaparin","RECRUITING","2026-06-18",{"date":30,"type":31},"2026-06-23","ACTUAL",{"date":33,"type":31},"2024-05-04",{"date":35,"type":20},"2027-08",{"name":37,"class":38},"Medical University of Vienna","OTHER",3,""]